FIND YOUR CONSULTANT
JOIN OUR COMMUNITY
FIND YOUR CONSULTANT
JOIN OUR COMMUNITY

Industries > 

Life Sciences > Biotechnology Practice > Labeling Strategy And Negotiation

Labeling Strategy And Negotiation

Service Line: Strategy

Finding the right consultant should be this easy.

1

Tell us about your project

2

Interview candidates

(We’ll provide bios within 48 hours on average)

3

Select your consultant and start work!

Find a consultant in our Biotechnology Practice

Prefer email? Write to [email protected]

Capability: Labeling Strategy And Negotiation

The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Biotechnology Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.

1) Client Situation

The client operated within the therapeutics-focused biotech ecosystem and required support with Labeling Strategy And Negotiation in the context of Biotechnology. Teams across Emerging Therapeutic Biotech (Preclinical), Clinical-Stage Biotech (Phase I–III), Commercial Biotech (Post-Approval), Platform Biotech (Therapeutic Discovery), and Biotech Investors & Incubators sought to align the Target Product Profile (TPP) and evidence to defensible claims; develop the Company Core Data Sheet (CCDS) and region-specific labels (USPI and SmPC); and execute labeling negotiations with FDA and EMA to secure competitive, compliant labels. The diagnostic surfaced concrete gaps that created regulatory, commercial, and timeline risk:

  • TPP–evidence misalignment
    • Endpoints and estimands in late-stage protocols did not fully support label-intended claims; PRO/HRQoL instruments and responder definitions were not pre-specified for claims; subgroup and enrichment rationales lacked statistical backing for label language.
  • Fragmented labeling ownership and processes
    • No cross-functional labeling governance with accountable owners for CCDS, USPI/SmPC, and Medication Guide/PIL; MLR/PRC and Regulatory Labeling were not synchronized; change control and CCDS-to-local label mapping were ad hoc.
  • CCDS maturity and variation planning
    • CCDS sections (Indications, Dosage and Administration, Contraindications, Warnings/Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations, Pharmacology) were incomplete; class labeling expectations and precedents were not benchmarked; a plan to cascade CCDS updates into regional labels post-approval was missing.
  • USPI/PLR and EU QRD compliance risk
    • US labeling in PLR format (highlights/full prescribing information) had drafting inconsistencies; SPL metadata and DailyMed readiness were not verified. EU SmPC/PIL/labeling texts were off-template; QRD and readability/user testing planning lagged.
  • CMC–label linkage unclear
    • Specifications, assay methods, device/combination instructions for use (IFU), and storage/stability claims were not translated into label-ready statements; comparability and post-approval changes (variations) did not have a labeling impact matrix.
  • Safety narrative and class effects
    • Boxed Warning thresholds, contraindications vs. warnings/precautions, and class labeling precedent were not analyzed; MedDRA grouping and tabulations for Adverse Reactions lacked consistency across ISS/ISE and draft label.
  • Negotiation readiness and calendars
    • Negotiation positions and fallbacks were not documented; there was no consolidated “label book” for mid-cycle labeling meetings, Day-120 list of questions (LoQ), or late-cycle reviews; agency labeling timelines were not integrated into the submission plan.
  • Global harmonization and translation
    • US/EU differences (indication scope, posology/dose, special populations, RMP/REMS elements) were not proactively mapped; translation quality and QRD harmonization planning were late-stage; CCDS deviations lacked documented justifications.
  • Performance indicators trending below target
    • Labeling review cycles exceeded plan; technical comments (PLR/QRD) recurred; SPL rejections occurred in testing; a high share of review issues centered on labeling sections, increasing first-cycle risk.

2) Project Objective

The primary objective focused on aligning the TPP, evidence, and claims; creating a robust CCDS; drafting and governing USPI/SmPC; and executing labeling negotiation strategies with FDA and EMA to secure competitive labels while maintaining compliance and inspection readiness.

Secondary objectives included:

  • Converging cross-functional claims and drafting a single labeling narrative consistent across Modules 2/5 and Module 3 constraints.
  • Building a CCDS and governance model with change control, decision logs, and cascade rules for regional labels.
  • Authoring PLR-compliant USPI and QRD-compliant SmPC/PIL/labeling texts; verifying SPL and QRD technical compliance.
  • Preparing negotiation positions and fallback language; running mock labeling sessions and late-cycle reviews with “redline” playbooks.
  • Linking CMC specifications, stability, and device IFU to label content; planning for post-approval variations and label maintenance.
  • Coordinating safety labeling (boxed warnings, contraindications, warnings/precautions) with class labeling precedent and benefit–risk narrative.
  • Integrating labeling timelines with submission and review clocks (US Day-74/mid-cycle/late-cycle; EU Day-120/clock stop; UK/HC/JP variants).
  • Standing up quality checks (PLR, QRD, SPL) and translation workflows with vendor governance and SLAs.

3) Methodology and Approach

Workstream 1: TPP and Claims Convergence

We aligned clinical, statistical, safety, CMC, HEOR, and commercial stakeholders on claims and evidence thresholds.

  • Claims matrix: mapped each intended claim to endpoints, estimands, sensitivity analyses, PRO/HRQoL instruments, and safety datasets; flagged gaps and feasible alternatives.
  • Precedent review: analyzed competitor labels, class labeling, EPARs, FDA reviews, and advisory committee trends to calibrate ambition and risk.
  • Decision log: documented primary/fallback positions with rationales and data references.

Workstream 2: CCDS Development and Governance

We authored and operationalized the Company Core Data Sheet as the backbone for global labeling.

  • CCDS drafting: built core sections (Indications, Dosage, Contraindications, Warnings/Precautions, Adverse Reactions, Interactions, Use in Specific Populations, Overdosage, Pharmacology, Clinical Studies) aligned to evidence.
  • Governance: established a Labeling Committee (Regulatory Labeling, Clinical, Safety, CMC, Medical, HEOR/Access, Legal) with charters, meeting cadence, change control SOP, and CCDS deviation rules for local labels.
  • Lifecycle: created a CCDS-to-regional mapping and update process for post-approval changes (signals, variations, safety updates), including CCDS versioning and justification templates.

Workstream 3: USPI/SmPC Authoring and Technical Compliance

We produced US and EU labels that met format and style expectations.

  • USPI: authored PLR-compliant highlights and FPI; ensured cross-reference coherence with ISS/ISE and CSR; validated SPL elements (section IDs, route, dosage forms, NDCs, RxCUI where applicable); prepared Medication Guide as required.
  • EU SmPC/PIL/Labeling: drafted QRD template-compliant texts; managed readability/user testing plans for PIL; synchronized translations and QRD checklists; harmonized PI/SmPC divergences with CCDS rationales.
  • QC: implemented line-by-line QC for PLR/QRD, hyperlinks, cross-references, tables/figures, and consistency with datasets and Module 2 summaries.

Workstream 4: Safety Labeling Strategy

We defined risk statements and class labeling positions grounded in benefit–risk.

  • Signal evaluation: reviewed safety database thresholds and signal detection outputs; prepared class effect analyses and MedDRA groupings for AR tables; aligned SAE/AE frequencies and severity grading with label conventions.
  • Risk statements: authored and tested scenarios for boxed warning triggers vs. warnings/precautions; defined contraindications; aligned REMS/RMP implications with label content.

Workstream 5: CMC–Label Interface

We translated product quality and device IFU into label-ready content.

  • Specifications/assays: validated language for product description, excipients, storage/handling, preparation, and administration; aligned assay methods and stability claims to filing evidence.
  • Comparability/variations: created a labeling impact matrix for process changes and scale-up; drafted pre-approved variation narratives for label alignment post-approval.
  • Combination products: integrated device IFU and human factors testing outputs into labeling language where applicable.

Workstream 6: Negotiation Strategy and Mock Sessions

We prepared teams to advocate for competitive language and manage trade-offs.

  • Label book: compiled annotated labels (ours vs. precedent), data justifications, and redline proposals with pros/cons and fallback text.
  • Mock meetings: rehearsed mid-cycle, late-cycle, and EU Day-120/clock-stop negotiations; assigned roles (lead negotiator, safety/clinical/CMC SMEs, scribe); refined scripts and responses.
  • Minute strategy: prepared position papers for labeling meetings, proposed wording, and minute negotiation approaches to preserve optionality.

Workstream 7: Global Harmonization and Translation

We synchronized CCDS, USPI, SmPC, and local labels.

  • Harmonization matrix: mapped claims and safety language across regions; documented justified differences; managed alignment cycles with translators and in-country reviewers.
  • Translation and QRD: set SLAs, terminology glossaries, and QC loops for translations; planned readability/user testing timelines; established QBRs with vendors.

Workstream 8: Timelines, Clock Management, and Response Engine

We embedded labeling milestones in the submission plan and built rapid-response capability.

  • Clock integration: aligned labeling deliverables to Day-74 package, mid-cycle/late-cycle meetings, and EU Day-120/clock-stop workflows; prepared SPL/labeling-submission runbooks.
  • Response engine: established intake, drafting, and sign-off workflows for labeling questions; prepared evidence libraries (ISS/ISE/CSR excerpts, safety tables, comparator labels) and templated response letters.

Workstream 9: Quality Controls and SPL/QRD Readiness

We ensured technical acceptance and minimized rework.

  • Technical checks: built PLR and SPL validators; verified QRD compliance, naming, versioning, and lifecycle operators; performed dry-run submissions to test portals (where permissible).
  • Document controls: enforced metadata, audit trails, and change histories across label versions; mapped SPL to DailyMed requirements and verified content-of-labeling packaging.

Workstream 10: Post-Approval Labeling and CCDS Maintenance

We created a durable model for label evolution.

  • Signal-to-label: defined triggers for CCDS updates (safety signals, additional indications, post-approval studies); integrated PSUR/PBRER learnings; scripted variation filing sequences.
  • Governance: instituted quarterly CCDS reviews, deviation logs, and cascade timelines to local labels; aligned with promo review constraints.

4) Data Request

We requested datasets and artifacts required to execute labeling strategy and negotiation across regions. Typical horizons were current late-stage program documentation and 6–18 months forward for submission and review calendars.

  • Clinical efficacy/safety:
    • ISS/ISE outputs, CSR drafts, SAP/estimands, subgroup analyses, sensitivity analyses, PRO/HRQoL validation, eCOA plans, exposure–response/PK-PD summaries, QTc data (if applicable).
  • Safety and PV:
    • Adverse event tabulations (MedDRA), SAE narratives, signal detection outputs, benefit–risk assessments, REMS/RMP concepts, class-labeling precedent, pooled safety datasets.
  • CMC and combination product:
    • Specifications, analytical methods and validation, stability data, storage/preparation/administration instructions, comparability plans, PPQ/CPV status, device IFU and human factors testing summaries.
  • Regulatory and precedent:
    • Competitor labels, class labeling, EPARs/FDA review summaries, prior agency correspondence and labeling comments, advisory committee materials (if any), internal labeling decks/position logs.
  • Templates and toolchain:
    • Current USPI/SmPC/PIL templates, SPL exports, QRD checklists, translation glossaries, labeling QC checklists, label management repositories and audit trails.
  • TPP and access:
    • Current TPP/label hypothesis, HEOR endpoints, payer insights, HTA requirements, promo claims priorities and MLR constraints.
  • Planning:
    • Submission Gantts, labeling meeting calendars (US/EU), resource plans, vendor SLAs and capacity calendars; blueprint for DailyMed and EU portal submissions.

Common data pitfalls included inconsistent endpoint definitions for claims, incomplete PRO validation packages, fragmented safety tables and MedDRA groupings, missing CMC–label linkages (storage/handling, IFU), outdated templates, inconsistent SPL metadata, and lack of translation/QRD planning. We established a labeling data room, templates, and a CCDS/USPI/SmPC mapping before drafting and negotiation rehearsals.

5) Questions for Client

  • What are the priority claims in the TPP, and what evidence thresholds (effect size, durability, PRO) are acceptable to secure them?
  • Where are you willing to take risk on indication scope and population definitions (e.g., enrichment, biomarker subsets) vs. secure broader class language?
  • What is your position on boxed warning vs. warnings/precautions; what class-labeling precedents constrain choices?
  • How should we prioritize US vs. EU differences (indication wording, posology, special populations) if evidence diverges?
  • Which PRO/HRQoL claims are essential for access, and what validation and analysis plan supports them?
  • Which safety signals and subgroup findings require proactive language proposals or fallbacks?
  • What CMC elements (storage, prep/admin, IFU, comparability) are non-negotiable for the initial label; what variation pathways will follow?
  • What negotiation posture do you prefer (assertive vs. conservative); who approves fallback positions in real time during labeling meetings?
  • What SPL/QRD, translation, and readability risks must we mitigate; what rework tolerance exists near filing?
  • What governance cadence and escalation thresholds should the Labeling Committee enforce pre- and post-approval?
  • What promotion and payer considerations (MLR/PRC, HEOR) must align with the CCDS and regional labels at approval?

6) Interview Guide for Subject Matter Experts

Head of Regulatory Labeling / Global Labeling Lead

  • Which claims are highest priority and most defensible; where are fallback positions acceptable?
  • What lessons from competitor labeling and class guidance shape our strategy?
  • How should CCDS deviations be justified and documented for local labels?
  • Where have PLR/SPL or QRD/translation issues occurred previously; what prevention is feasible?
  • What governance cadence is needed to lock drafts and handle late data shifts?

Clinical / Medical Lead

  • Which endpoints and estimands underpin claims; where are sensitivity analyses strongest/weakest?
  • What PRO/HRQoL evidence is label-credible; what caveats may limit language?
  • Which subgroups or enrichment strategies belong in labeling vs. publications?
  • How will we address intercurrent events in plain-language label text?

Biostatistics Lead

  • What magnitude and precision support specific claims; how will multiplicity and interim decisions affect labeling strength?
  • What subgroup and responder analyses are robust enough for label incorporation?
  • How can we translate estimands into reviewer-friendly summaries for label negotiations?

Safety / Pharmacovigilance Lead

  • Which risks warrant boxed warnings vs. warnings/precautions; what class effects are likely to apply?
  • How should AE/AR tables and frequency thresholds be constructed; where do MedDRA groupings drive clarity?
  • What REMS/RMP implications may arise from proposed safety statements?

CMC / MSAT / Device (if applicable)

  • Which stability/storage/administration statements are evidence-ready; where do specs or IFU constrain wording?
  • How will comparability and post-approval changes impact labeling; what variation plan is realistic?
  • What artwork or IFU dependencies exist for device/combination products?

HEOR / Market Access

  • Which payer-relevant outcomes or PRO claims are critical; how do HTA expectations differ from regulatory?
  • What trade-offs in label wording will impact value dossiers and coverage?

Medical Affairs / Promo Review (MLR/PRC)

  • What promotional claims require label language to enable compliant messaging?
  • Where have prior review bodies challenged statements; what phrasing avoids misbranding risk?

7) Timeline

We executed a 12–14 week plan with decision gates tailored to Labeling Strategy And Negotiation within Regulatory Affairs.

  • Weeks 1–2: Diagnostic and TPP Alignment
    • Assessed evidence vs. claims; reviewed precedent labels and class guidance; drafted claims matrix and decision log; confirmed governance cadence.
    • Decision Gate A: Approved priority claims, fallback positions, and CCDS outline; locked negotiation posture.
  • Weeks 3–4: CCDS Draft and USPI/SmPC Skeletons
    • Authored CCDS v1; drafted USPI PLR highlights and section skeletons; built SmPC QRD-compliant baseline; created QC checklists; aligned with Module 2/5 narratives.
    • Decision Gate B: Ratified CCDS v1 and regional baselines; approved QC standards and translation/QRD plan.
  • Weeks 5–6: Safety Labeling and CMC–Label Interface
    • Finalized safety tables and proposed risk statements; mapped CMC content (storage, prep/admin, IFU, comparability) into draft labels; created variation impact matrix.
    • Decision Gate C: Approved safety language proposals and CMC-linked label content; authorized mock negotiations.
  • Weeks 7–8: Mock Negotiations and Harmonization
    • Ran labeling rehearsal sessions; iterated label book and redlines; harmonized US/EU language; set translation glossaries and QRD checkpoints; validated SPL metadata/SPL packaging approach.
    • Decision Gate D: Cleared negotiation playbook and harmonized drafts; confirmed vendor SLAs and capacity.
  • Weeks 9–10: Technical Compliance and Submission Integration
    • Executed PLR/QRD technical checks; performed SPL/portal dry-run (where permissible); embedded labeling milestones into submission plan (Day-74, mid-/late-cycle, Day-120/clock-stops); stood up response engine.
    • Decision Gate E: Passed technical readiness; locked submission and review calendars for labeling.
  • Weeks 11–12: Finalization and Governance Handoff
    • Closed QC comments; approved CCDS and regional drafts for submission; finalized governance SOPs for CCDS maintenance and post-approval changes; trained teams on negotiation and response workflows.
    • Decision Gate F: Authorized use in submission packages; set post-approval labeling cadence.
  • Weeks 13–14 (optional): Late-Cycle Drill and Translation QA
    • Simulated late-cycle negotiations and EU clock-stop resolution; completed translation QA and readability planning; tuned response engine templates.

Critical path items included PRO/HRQoL validation for claims, safety signal thresholds for boxed warning vs. warnings/precautions, CMC-derived statements (storage/administration, IFU), class labeling constraints, SPL/QRD technical checks, translation readiness, and alignment of labeling milestones with submission clocks.

8) Deliverables

  • Claims Matrix and Decision Log
    • Mapping of TPP claims to evidence, precedents, and fallback language; governance record of decisions and rationales.
  • Company Core Data Sheet (CCDS) and Governance Charter
    • CCDS v1 with versioning; labeling committee charter; change control SOP; CCDS deviation and cascade rules to local labels.
  • USPI (PLR) and SmPC/PIL/Labeling Drafts
    • PLR-compliant highlights/FPI; QRD-compliant SmPC, PIL, and labeling texts; annotated justifications and cross-references to ISS/ISE/CSR and Module 3.
  • Safety Labeling Dossier
    • Risk statements (boxed warning/warnings/precautions), class labeling analysis, adverse reactions tables (MedDRA), REMS/RMP linkages, and benefit–risk narrative.
  • CMC–Label Integration Pack
    • Storage/stability/administration language; IFU excerpts for combination products; comparability/variation impact matrix; cross-links to Module 3.
  • Label Negotiation Playbook and Label Book
    • Annotated competitor and internal redlines; negotiation scripts; minute negotiation strategies; Q&A grids.
  • Technical Compliance and SPL/QRD Toolkit
    • PLR/QRD checklists; SPL packaging and metadata guide; dry-run reports; portal submission runbooks and receipt capture SOPs.
  • Harmonization and Translation Plan
    • US/EU alignment matrix; translation glossaries; vendor SLAs; QRD/readability plans; QA procedures.
  • Clock and Response Engine Package
    • Labeling calendars; response templates; evidence libraries; workflow and escalation maps for mid-/late-cycle and clock-stop interactions.
  • Post-Approval Labeling Governance
    • CCDS maintenance SOPs; signal-to-label triggers; variation filing sequence; cadence for local label cascades; training materials.

9) Industry Insights

  • Labels are evidence-constrained and precedent-aware
    • Competitive labels emerge when claims are tied to robust effect sizes, estimands, and clinically meaningful endpoints; class labeling and safety communications define a practical ceiling.
  • PRO/HRQoL claims require forethought
    • Instrument selection, validation, and analysis plans must be prespecified; post hoc analyses rarely sustain label language, and reviewers prioritize interpretability.
  • Boxed warnings vs. warnings/precautions hinge on magnitude and plausibility
    • Early, structured benefit–risk framing and class effect analysis prevent late-cycle surprises; contradictory safety tabulations erode negotiation credibility.
  • CCDS governance determines global agility
    • A disciplined CCDS process with change control and deviation rules accelerates aligned updates across regions and reduces inspection and promo risk.
  • CMC narratives shape dosing, storage, and IFU
    • Specifications, stability, and device usability must translate cleanly into label statements; weak CMC–label linkage invites IRs and restrictive language.
  • Technical hygiene avoids avoidable delays
    • PLR/QRD compliance, SPL metadata, and lifecycle operator correctness are predictable; dry runs and checklists keep labeling off the critical path.
  • Negotiation is a rehearsed discipline
    • Mock sessions, annotated redlines, and fallback positions raise the probability of favorable outcomes; minute negotiation preserves optionality and anchors future maintenance.
  • What “good” looks like
    • A unified claims matrix and CCDS; PLR/QRD-compliant labels; harmonized US/EU texts with justified differences; safety language aligned to class precedent; CMC-derived statements that withstand scrutiny; SPL/QRD technical readiness; and a trained team executing label negotiations against a clear calendar.
  • Near-term watch points
    • Evolving class labeling; PRO/HRQoL evidentiary expectations; readability and public disclosure policies; regional divergences on risk statements; and post-approval signal-to-label agility. Quarterly labeling governance and data refreshes keep strategies current.

Implications for clients we served included enabling Emerging Therapeutic Biotech to translate first pivotal data into a credible label strategy; supporting Clinical-Stage Biotech to prepare CCDS and negotiate USPI/SmPC language aligned to claims and class precedent; equipping Commercial Biotech to harmonize and maintain labels post-approval under a robust CCDS process; guiding Platform Biotech to standardize labeling playbooks across partnered programs; and giving Biotech Investors & Incubators visibility into labeling risk, competitive positioning, and first-cycle readiness across portfolios.

Selected Capabilities of our Biotechnology Practice

Strategy & Corporate Development

  • Corporate Strategy And Growth Agenda: Define enterprise ambition, where to play and how to win, therapeutic area focus, build-partner-buy choices, and value creation roadmap for biotech platforms and asset-centric companies.
  • Portfolio Strategy And Indication Prioritization: Optimize pipeline across modalities using rNPV (risk-adjusted net present value), Probability of Technical and Regulatory Success, and constraints to prioritize indications, sequencing, and kill/hold decisions.
  • Business Development And Licensing Strategy: Set business development and licensing (BD&L) strategy, target screening, and out-licensing/in-licensing approach; shape deal thesis, valuation, and term sheets to maximize partnering value and optionality.
  • M&A Strategy And Diligence: Develop biotech mergers and acquisitions (M&A) strategy, longlist, shortlist, and theses; lead commercial, pipeline, and synergy diligence with integration blueprint and carve-out or asset-swap options.
  • Capital Allocation And Investor Readiness: Design capital allocation across programs and platforms; craft investor narrative, valuation, and financing strategy (venture, crossover, IPO) to extend runway and reduce cost of capital.

Operations

  • Manufacturing Operations Excellence: Improve yield, OEE, and right-first-time across upstream, downstream, and fill-finish to cut deviations, cycle time, and cost of goods for biologics and advanced therapies.
  • Tech Transfer And Scale-Up Execution: Plan and execute GMP tech transfer and scale-up, aligning control strategy and PPQ readiness to accelerate time-to-quality and de-risk commercial launch for new modalities.
  • Capacity Modeling And Debottlenecking: Model end-to-end capacity and cycle times, identify bottlenecks, and redesign schedules, changeovers, and cleanroom utilization to unlock throughput and defer capital for biotech facilities.
  • QC Release Cycle Time Reduction: Optimize QC labs with sampling rationalization, Laboratory Information Management System (LIMS), method lifecycle management, and scheduling to shorten batch release times and improve on-time-in-full service.
  • External Manufacturing Performance Management: Set governance with external manufacturing partners, KPIs, escalation, and issue resolution to improve on-time-in-full, right-first-time, and tech transfer outcomes while protecting supply.

Supply Chain

  • Integrated Business Planning And Supply Planning: Build integrated business planning with constrained supply planning and multi‑echelon inventory optimization to improve service, inventory turns, and adherence across drug substance and product networks.
  • Supply Network Design And Footprint Strategy: Optimize network of drug substance and drug product sites, distribution centers, and third‑party logistics to balance total landed cost, service, and risk in make‑buy‑location decisions.
  • Cold Chain And Temperature-Controlled Logistics: Design cold chain strategy, packaging, and lane qualification for 2–8°C, frozen, and cryogenic shipments; enable real‑time monitoring and excursion management to reduce spoilage and write‑offs.
  • Supply Risk And Shortage Management: Build multi‑tier risk mapping, dual‑sourcing strategies, and allocation playbooks with scenario planning and control‑tower alerts to prevent stockouts and manage biologics supply disruptions.
  • Cell And Gene Therapy Orchestration: Design vein‑to‑vein supply chain, chain of identity and custody, apheresis slot scheduling, and courier control to cut turnaround time and failure risk for autologous therapies.

Procurement & Strategic Sourcing

  • Category Strategy And Strategic Sourcing: Build category strategies for GMP raw materials, single-use assemblies, primary packaging; execute e-sourcing and negotiations to deliver Cost of Goods Sold (COGS) reduction and resiliency.
  • CDMO/CRO Vendor Selection And Contracting: Structure sourcing of Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs); set Quality Agreements; negotiate capacity, pricing, and protections to de-risk delivery.
  • Should-Cost Modeling And Clean-Sheet Costing: Develop should-cost models for single-use assemblies, chromatography resins, media, vials, and contract services to set target prices and win fact-based negotiations.
  • Supplier Risk And Continuity Planning: Conduct supplier and tier-2 risk assessments for plasmids, viral vectors, resins; secure long-term agreements, dual-source contracts, and indexation clauses to ensure continuity and price stability.
  • Supplier Relationship Management And Governance: Establish segmentation, joint business plans, Quarterly Business Reviews (QBRs), Key Performance Indicators (KPIs), and innovation pipelines to improve on-time-in-full, quality, and access to new technologies.

R&D & CMC

  • CMC Strategy And IND Readiness: Define phase-appropriate CMC strategy, control plans, and dossier-ready packages to accelerate IND (Investigational New Drug) submissions and de-risk early clinical manufacturing.
  • Process Development And Characterization: Design and optimize upstream and downstream processes using Design of Experiments, scale-down models, and process characterization to achieve titer, purity, and robustness targets pre-transfer.
  • Analytical Development And Method Lifecycle: Build potency, purity, identity, and safety assays; qualify and validate methods; design stability programs to enable release, comparability, and control of critical quality attributes (CQAs).
  • Formulation And Drug Product Development: Develop phase-appropriate formulations, excipient strategies, and container-closure systems for biologics, mRNA, and viral vectors to improve stability, usability, and shelf life.
  • Comparability And Post-Change Strategy: Plan comparability protocols, risk assessments, and bridging analytics for process changes, site moves, or scale-up to protect product quality and avoid clinical rework.

Organization

  • Operating Model And Organizational Design: Design stage-appropriate biotech operating model across R&D, CMC, Clinical, Quality, Supply, and Commercial; align structure, decision rights, and governance to accelerate development and launch.
  • Leadership And Governance Effectiveness: Strengthen executive cadence, board interfaces, decision forums, and RACI (Responsible, Accountable, Consulted, Informed) clarity to speed decisions, resolve cross-functional issues, and drive accountability.
  • Talent Strategy And Workforce Planning: Build capability maps, workforce plans, and location strategy for bioinformatics, process development, regulatory, and commercial roles to meet milestones while optimizing cost and flexibility.
  • Ways Of Working And Agile Implementation: Implement agile teams in R&D and CMC, meeting redesign, OKRs (Objectives and Key Results), and collaboration norms to increase throughput, transparency, and reduce cycle time.
  • Scaling From Virtual To Commercial Organization: Plan build-out of Quality, Supply, and Commercial functions; define roles, spans and layers, and shared services to scale efficiently before first launch.

Marketing

  • Brand Strategy And Positioning: Define biotech brand narrative, target segments, value proposition, and messaging architecture to differentiate in rare and specialty indications and drive HCP and patient preference.
  • Omnichannel HCP Engagement And Content Operations: Design omnichannel journeys, modular content, and channel mix across email, rep-triggered, web, and social to increase HCP reach, engagement, and conversion within regulatory constraints.
  • Key Opinion Leader And Community Influencer Strategy: Map and activate key opinion leaders (KOLs), digital opinion leaders; co-create education, publications, and advisory forums to build credibility and accelerate guideline inclusion and adoption.
  • Launch And Prelaunch Excellence: Build evidence-driven launch plans, disease awareness, patient-finding, and HCP activation; sequence milestones, content, and congresses to maximize share of voice and first-year uptake.
  • Marketing Performance And ROI Analytics: Build dashboards, marketing-mix models, and experimentation to attribute impact, optimize spend, and improve return on investment (ROI) across HCP, patient, and digital channels.

Pricing

  • Launch Pricing And Price Corridor Design: Define Wholesale Acquisition Cost (WAC) and ex-US list prices, price corridors, and price-volume curves by indication to balance access, uptake, and lifetime revenue.
  • Gross-To-Net Optimization: Diagnose rebate, chargeback, copay, 340B Drug Pricing Program (340B), Medicaid Best Price leakages; design contracting, accruals, and governance to improve net price and predictability.
  • Outcomes-Based And Innovative Contracting: Structure outcomes-based contracts, annuity payments, and warranties for gene and cell therapies; define metrics, data flows, and risk-sharing to secure access and net revenue.
  • International Reference Pricing And Launch Sequencing: Model cross-border reference rules, parallel trade, and price spillover; optimize country sequencing, tender posture, and corridors to protect global net price.
  • IRA And Price Renegotiation Readiness: Build Inflation Reduction Act (IRA) strategy, revenue risk scenarios, and negotiation playbooks; adjust contracting, launch timing, and portfolio mix to mitigate price erosion.

Sales

  • Field Force Sizing And Territory Design: Optimize field force size, territories, Customer Relationship Management (CRM) call plans, and routing to maximize healthcare professional (HCP) coverage and productivity for biotech specialty therapeutics.
  • Key Account Management Enablement: Establish Key Account Management (KAM) model for Integrated Delivery Networks (IDNs) and centers of excellence with planning, access pull-through, and cross-functional engagement to drive adoption.
  • Incentive Compensation And Sales Performance Management: Design compliant incentive plans, quotas, and scorecards; align to new patient starts, persistency, and access status to drive specialty biotech revenue growth.
  • Specialty Pharmacy And Hub Pull-Through: Orchestrate specialty pharmacy and patient support hub processes to reduce time-to-fill, improve benefits verification, and increase therapy initiation and adherence for complex treatments.
  • Sales Training And Field Readiness: Develop disease-state and clinical selling curricula, objection handling, and certification; equip field teams with compliant materials and tools to accelerate launch uptake and competitive wins.

Finance

  • FP&A And Runway Management: Build integrated cash, P&L, and scenario models; align to milestones and business development (BD) events; enable rolling forecasts to extend runway and optimize burn.
  • Product Costing And COGS Transparency: Establish standard costing, variance tracking, lot-level analytics, and transfer pricing to improve Cost of Goods Sold (COGS) predictability and margin decisions for biologics.
  • Working Capital Optimization: Optimize inventory policies, supplier terms, and collaboration cash schedules; redesign milestone invoicing to improve cash conversion cycle and fund critical programs.
  • Record To Report And Fast Close: Redesign close processes, chart of accounts, and Sarbanes-Oxley (SOX) controls to enable accurate inventory valuation, capitalization, and fast, audit-ready closes.
  • Collaboration And Revenue Recognition Advisory: Interpret Accounting Standards Codification (ASC) 606 for licenses, milestones, and cost-sharing; design policies, accruals, and systems to ensure compliant, audit-ready biotech revenue recognition and disclosures.

AI, Data & Analytics

  • Biotech Data Platform And Governance: Build FAIR, GxP-compliant data platforms with ontologies and master data to unify preclinical, CMC, clinical, and commercial datasets for analytics, interoperability, and data integrity.
  • CMC Digital Twins And Process AI: Develop bioprocess digital twins, multivariate control, and soft sensors to predict critical quality attributes, boost yield, and reduce deviations, cycle time, and cost.
  • Generative AI Copilots For CMC And Quality: Deploy large language models (LLMs) with Retrieval-Augmented Generation (RAG) for authoring, querying, and change-impact analysis; ensure validation, permissions, and audit trails in regulated environments.
  • RWE And Clinical AI For Trial Acceleration: Build real-world evidence pipelines and machine learning for patient finding, eligibility inference, and site selection to accelerate enrollment and improve protocol feasibility.
  • MLOps And Model Risk Management: Establish data pipelines, feature stores, versioning, monitoring, and validation with model risk controls and change management to safely scale AI in GxP settings.

Transformation

GxP Quality & Compliance

  • Quality Management System Design And Maturity Uplift: Design risk-based QMS aligned to ICH Q10; optimize SOPs, governance, roles, and metrics to meet GMP/GLP/GCP expectations and accelerate approvals and batch release.
  • Inspection Readiness And Remediation: Run risk-based inspection readiness with mock audits, storyboards, SME coaching, and day-in-the-life war rooms; lead remediation and CAPA plans to close FDA/EMA observations.
  • Data Integrity And Computerized Systems Assurance: Assess ALCOA+ data integrity, remediate gaps, and implement risk-based Computer Software Assurance; validate eQMS, LIMS, MES, and analytics with lifecycle controls and audit trails.
  • Deviation CAPA And Change Control Excellence: Redesign deviation, root cause analysis, CAPA effectiveness, and change control workflows; implement analytics and right-first-time behaviors to reduce recurrence, cycle time, and compliance risk.
  • External Partner Quality Oversight And Audits: Establish risk-based oversight for CDMOs, CROs, and suppliers; set Quality Agreements, audit programs, and release-by-exception to strengthen compliance, tech transfer outcomes, and supply reliability.

Program & Portfolio Management

Information Technology

  • IT Strategy And Enterprise Architecture: Define IT strategy, target architecture, and systems roadmap across ERP, MES, LIMS, QMS, CTMS, and EDC to enable scale, compliance, and faster launch readiness.
  • Core Systems Selection And Implementation Readiness: Run vendor selection for ERP, Veeva Vault Quality/Regulatory, MES, LIMS, and CTMS; define requirements, integrations, and implementation governance to de-risk delivery.
  • Cloud And Infrastructure Modernization: Design secure, GxP-ready cloud architecture on AWS or Azure, with network standards and disaster recovery, improving agility, reliability, and cost transparency.
  • Cybersecurity And Identity Management: Build cybersecurity program with risk-based controls, identity and access management, privileged access, and OT segmentation to protect patient data, intellectual property, and manufacturing assets.
  • IT Operating Model And Service Management: Design IT operating model, ITIL processes, and service catalog; establish SLAs, DevSecOps, and vendor management to improve service quality, delivery speed, and compliance.

Regulatory Affairs

  • Global Regulatory Strategy And Agency Engagement: Define IND/CTA-to-BLA/MAA strategy, pursue orphan, Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and PRIME designations, and lead health authority interactions to de-risk development and approvals.
  • Submission Planning And eCTD Readiness: Build submission roadmap, authoring plan, Module 2/3 strategy, vendor/publisher governance, and quality checks to deliver first-cycle, on-time eCTD submissions across regions.
  • Labeling Strategy And Negotiation: Align Target Product Profile, evidence, and claims; lead core data sheet, USPI/SmPC development, negotiation strategies, and CCDS governance to secure competitive labels.
  • Post-Approval Lifecycle And Variations Management: Design regulatory pathways for post-approval changes; prepare supplements and variations, manage commitments, and harmonize dossiers to sustain global compliance and supply continuity.
  • Companion Diagnostic And Combination Product Regulatory Strategy: Define CDx co-development and combination product strategy, classification, and submission pathways; coordinate interactions with FDA device and drug centers to synchronize approvals and enable precision therapy access.

Clinical Development & Operations

  • Protocol Design And Operational Feasibility: Optimize protocol endpoints, eligibility, visit schedules, and assessments using feasibility and real-world data to cut screen failure, patient burden, cost, and cycle time.
  • Country And Site Strategy: Use epidemiology, investigator performance, and startup cycle time data to select countries and sites, set allocations, and build contingency to achieve predictable enrollment.
  • Patient Recruitment And Retention Acceleration: Deploy patient finding, referral networks, decentralized visits, eConsent, diversity plans, and travel support to accelerate enrollment, cut discontinuations, and improve last patient out predictability.
  • Risk Based Quality Management And Monitoring Optimization: Implement risk based quality management per Good Clinical Practice, central monitoring, tolerance limits, and source verification to lower queries, deviations, and monitoring cost.
  • CRO Oversight And Performance Management: Establish sponsor oversight aligned to Good Clinical Practice with KPIs, tolerance limits, issue escalation, and corrective action governance to improve CRO on-time delivery and quality.

Market Access & HEOR

  • Payer Value Proposition And Access Strategy: Define payer value proposition, unmet need, comparators, and access milestones; shape P&T and prior authorization criteria to secure rapid, broad coverage for specialty biologics.
  • Global HTA Strategy And Dossier Development: Develop global value dossier and AMCP dossier; plan NICE, G-BA, SMC, HAS submissions; tailor evidence and narratives to achieve first-cycle HTA approvals.
  • Health Economic Modeling And Evidence Synthesis: Build cost-effectiveness and budget impact models, partitioned survival or Markov; conduct indirect treatment comparisons and network meta-analyses to meet HTA and payer requirements.
  • Real-World Evidence For Value Demonstration: Design RWE strategy including registries, external control arms, and burden-of-illness studies; generate endpoints and PROs supporting HTA, ICER reviews, label expansions, and reimbursement renewals.
  • Coding Coverage And Reimbursement Strategy: Establish coding pathways, HCPCS/CPT/ICD-10 strategies, compendia listings, and site-of-care economics to secure coverage, appropriate payment, and patient affordability across channels.

Connect with the right consultant

Umbrex rapidly connects you with independent professionals who combine top‑tier consulting experience at firms such as McKinsey, Bain, Boston Consulting Group with hands‑on roles.

Find a consultant in our Biotechnology Practice

Prefer email? Write to [email protected]